Although KMT2A-PTD has been recognized as a high-risk molecular feature in the International Prognostic Scoring System-Molecular (IPSS-M) in MDS [53], its prognostic significance in AML remains controversial [35,54]. This evidence concerns the gene BCS1L and acute myeloid leukemia.